Market News AIOpen the app

Alamar Biosciences showed off its NULISA platform in 46 talks at the CTAD 2026 conference.

MarketRead the original at globenewswire.com
Good for ALMR

Alamar’s NULISA platform is being used in 46 CTAD research presentations, including 10 oral talks. This wider research use may raise its profile, though the announcement gives no sales or study results.

ALMR · Alamar Biosciences, Inc.

AI read · Good for ALMR

The AI's read

Use by researchers gives Alamar’s platform visibility in Alzheimer’s research and supports its role in measuring blood proteins. The announcement does not report sales or study results, so it shows research interest rather than proven business gains.

Get alerts for ALMR

Follow Alamar Biosciences, Inc. (ALMR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALMR
Free on the App Store and Google Play, or on the web.